Compare Avantis International Small Cap Value ETF (AVDV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Novavax Inc — how do they compare? Avantis International Small Cap Value ETF trades at $105.24, while Novavax Inc trades at $8.46 (market cap $1.38B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $11.19 |
52-Week Low | $80.02 | $6.22 |
Market Cap | — | $1.38B |
Enterprise Value | — | $889.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $103.10, down 1.06% with a bearish technical signal from moving averages. Recent news highlights strong 2026 performance with international small-cap value strategies delivering 35% gains while paying dividends. The fund's commodity exposure has cooled after driving outperformance, shifting the forward setup.
The outlook remains mixed with technical indicators signaling caution but positive sentiment around international small-cap value diversification. Key risks include commodity volatility and regional economic exposure, while institutional interest grows with Farther Finance increasing holdings by 165.8% in Q4 2025.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
